HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for Immunovant (NASDAQ:IMVT) and raised its price target from $26.00 to $27.00. Shares of Immunovant are currently trading down 3.77% at $22.86 per share.
May 23, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains Buy rating for Immunovant and raises price target to $27.00. Shares are trading down 3.77% at $22.86.
The maintained Buy rating and increased price target by HC Wainwright & Co. indicate a positive outlook for Immunovant's stock. Despite the current 3.77% decline in share price, the new price target of $27.00 represents an 18.14% increase from the current trading price, which could lead to a short-term positive impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100